

RiaSTAP (FIBRINOGEN)

DRUG CLASS	Haemostatic agent
AVAILABILITY	Vial contains 1 g of human fibrinogen. Also contains albumin, arginine hydrochloride, sodium hydroxide, sodium chloride and sodium citrate. Supplied with a diluent vial of 50 mL of water for injections, a transfer device, dispensing pin and filter. ¹ Contains 7.1 mmol of sodium. ¹
WARNING	RiaSTAP is a blood product. Check your local guidelines for handling, storage and batch recording requirements. Hypersensitivity reactions including anaphylaxis may occur.
pH	No information
PREPARATION	Allow the vial and diluent to reach room temperature. ¹ Use a flat, level surface and keep the RiaSTAP vial upright. Do not tilt the vials or transfer device to avoid loss of the vacuum and prevent wastage. Remove the safety cap from one end of the transfer device and insert into the stopper of the RiaSTAP vial. Remove the safety cap from the other end of the transfer device, invert the diluent vial and gently push the stopper into the end of the transfer device. Discard the empty diluent vial and the transfer device. Gently swirl the RiaSTAP vial until dissolved, it usually take 5 to 10 minutes but may take up to 15 minutes. Do not shake. ¹ Remove the dispensing pin from its outer packaging and insert into the stopper of the RiaSTAP vial, then remove the cap. Remove the filter from its packaging and attach a syringe. Screw the filter (with syringe attached) into the top of the dispensing pin and withdraw the dose. ¹ The solution is clear to slightly opalescent and colourless. The concentration is approximately 20 mg/mL of human fibrinogen. ¹
STABILITY	Vial: store at 2 to 8 °C. Protect from light. Do not freeze. ¹ Reconstituted solution: use within 6 hours of reconstitution. Do not refrigerate. ¹
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Inject slowly at a rate of 5 mL/minute, or slower if not tolerated by the patient. ¹
IV infusion	Inject slowly at a rate of 5 mL/minute, or slower if not tolerated by the patient. ¹
COMPATIBILITY	
Fluids	Sodium chloride 0.9% can be used to flush the line
Y-site	No information
INCOMPATIBILITY	Do not mix blood products with other medicines
SPECIAL NOTES	High or repeated doses are associated with a risk of thrombosis. Monitor the patient closely for signs of thrombosis, embolism, disseminated intravascular coagulation or myocardial infarction. ¹

REFERENCES

1. Product information. Available at www.tga.gov.au. Accessed 27/08/2020.